IPS and other prognostic factors in patients with advanced-stage disease in the modern-era treated with ABVD chemotherapy
| . | n = 173 (%) . | 5-y PFS (%) . | P value . | 5-y OS (%) . | P value . |
|---|---|---|---|---|---|
| Age, y | |||||
| 60-69 | 105 (61) | 68 | .003 | 68 | .005 |
| 70-79 | 60 (35) | 49 | 47 | ||
| ≥80 | 8 (4) | 47 | 47 | ||
| Sex | |||||
| Male | 110/173 (64) | 62 | .54 | 63 | .24 |
| Female | 63/173 (36) | 59 | 66 | ||
| Albumin ≥ 40 g/L | 39/146 (27) | 69 | .39 | 75 | .39 |
| Albumin < 40 g/L | 107/146 (73) | 56 | 57 | ||
| Hemoglobin ≥ 105 g/L | 117/168 (70) | 67 | .021 | 71 | .012 |
| Hemoglobin < 105 g/L | 51/168 (30) | 50 | 52 | ||
| White blood cells < 15 × 109/L | 153/173 (88) | 65 | .001 | 68 | .006 |
| White blood cells ≥5 × 109/L | 15/168 (12) | 32 | 39 | ||
| Lymphocytes ≥ 0.6 × 109/L and/or 8% | 113/162 (60) | 68 | .094 | 74 | .019 |
| Lymphocytes < 0.6 × 109/L and/or 8% | 49/162 (40) | 47 | 46 | ||
| Stage II-III | 102/173 (59) | 64 | .082 | 70 | .025 |
| Stage IV | 71/173 (41) | 57 | 56 | ||
| IPS 1-3 | 98/173 (57) | 71 | <.001 | 75 | <.001 |
| IPS ≥ 4 | 75/173 (43) | 47 | 49 | ||
| PS 0-1 | 94/171 (55) | 73 | .003 | 76 | .009 |
| PS ≥ 2 | 77/171 (45) | 46 | 51 | ||
| No B symptoms | 53/173 (31) | 66 | .75 | 71 | .71 |
| B symptoms | 120/173 (69) | 58 | 61 | ||
| Nonbulky | 140/166 (84) | 60 | .57 | 59 | .53 |
| Bulky | 26/166 (16) | 64 | 64 |
| . | n = 173 (%) . | 5-y PFS (%) . | P value . | 5-y OS (%) . | P value . |
|---|---|---|---|---|---|
| Age, y | |||||
| 60-69 | 105 (61) | 68 | .003 | 68 | .005 |
| 70-79 | 60 (35) | 49 | 47 | ||
| ≥80 | 8 (4) | 47 | 47 | ||
| Sex | |||||
| Male | 110/173 (64) | 62 | .54 | 63 | .24 |
| Female | 63/173 (36) | 59 | 66 | ||
| Albumin ≥ 40 g/L | 39/146 (27) | 69 | .39 | 75 | .39 |
| Albumin < 40 g/L | 107/146 (73) | 56 | 57 | ||
| Hemoglobin ≥ 105 g/L | 117/168 (70) | 67 | .021 | 71 | .012 |
| Hemoglobin < 105 g/L | 51/168 (30) | 50 | 52 | ||
| White blood cells < 15 × 109/L | 153/173 (88) | 65 | .001 | 68 | .006 |
| White blood cells ≥5 × 109/L | 15/168 (12) | 32 | 39 | ||
| Lymphocytes ≥ 0.6 × 109/L and/or 8% | 113/162 (60) | 68 | .094 | 74 | .019 |
| Lymphocytes < 0.6 × 109/L and/or 8% | 49/162 (40) | 47 | 46 | ||
| Stage II-III | 102/173 (59) | 64 | .082 | 70 | .025 |
| Stage IV | 71/173 (41) | 57 | 56 | ||
| IPS 1-3 | 98/173 (57) | 71 | <.001 | 75 | <.001 |
| IPS ≥ 4 | 75/173 (43) | 47 | 49 | ||
| PS 0-1 | 94/171 (55) | 73 | .003 | 76 | .009 |
| PS ≥ 2 | 77/171 (45) | 46 | 51 | ||
| No B symptoms | 53/173 (31) | 66 | .75 | 71 | .71 |
| B symptoms | 120/173 (69) | 58 | 61 | ||
| Nonbulky | 140/166 (84) | 60 | .57 | 59 | .53 |
| Bulky | 26/166 (16) | 64 | 64 |